S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

IPN Ipsen SA

114.50

-0.60 (-0.52%)

May 03 2024 - Closed

Delayed by 15 minutes

Ipsen S.A. publie ses comptes consolidés 2023

Ipsen S.A. publie ses comptes consolidés 2023

Ipsen S.A. - Etats financiers consolidés 2023

Pièce jointe

Ipsen - Comptes consolidés 2023

Ipsen (EU:IPN)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Ipsen Charts.

Ipsen (EU:IPN)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Ipsen Charts.

News

Ipsen appoints Keira Driansky as EVP, President of North America
Thursday 2 May 2024 (4 days ago) • GlobeNewswire Inc.

Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
Wednesday 24 April 2024 (2 weeks ago) • GlobeNewswire Inc.

Ipsen et Skyhawk Therapeutics annoncent la signature d'un accord de collaboration de recherche visant le ciblage d’ARN dans les maladies neurologiques rares
Monday 22 April 2024 (2 weeks ago) • GlobeNewswire Inc.

Ipsen publie son Document d’enregistrement universel 2023
Wednesday 17 April 2024 (3 weeks ago) • GlobeNewswire Inc.

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
Monday 8 April 2024 (4 weeks ago) • GlobeNewswire Inc.

Ipsen et Sutro Biopharma annoncent la signature d'un accord exclusif de licence mondiale pour un conjugué anticorps-petite molecule ciblant les tumeurs solides
Tuesday 2 April 2024 (1 month ago) • GlobeNewswire Inc.

Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Thursday 7 March 2024 (2 months ago) • GlobeNewswire Inc.

Ipsen S.A. publie ses comptes consolidés 2023
Thursday 15 February 2024 (3 months ago) • GlobeNewswire Inc.

Ipsen reçoit l’approbation de la FDA pour le schéma thérapeutique incluant Onivyde®, un potentiel nouveau traitement de référence en première ligne dans l'adénocarcinome du pancréas métastatique
Tuesday 13 February 2024 (3 months ago) • GlobeNewswire Inc.

Après de solides résultats pour l’année 2023, Ipsen anticipe quatre lancements commerciaux en 2024.
Wednesday 7 February 2024 (3 months ago) • GlobeNewswire Inc.

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
Tuesday 6 February 2024 (3 months ago) • GlobeNewswire Inc.

Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024
Monday 22 January 2024 (3 months ago) • GlobeNewswire Inc.

More News Articles

Voip Pal Com (QB)

Code Green Apparel (PK)

Kraig Biocraft Laborator... (QB)

Trump Media and Technology

Cann American (CE)

TheGlobe com (PK)

Northwest Biotherapeutics (QB)

Rennova Health (PK)

Lightwave Logic

TPT Global Tech (CE)

Anavex Life Sciences

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions